Ramachandran Plot Density Analysis for Genetic Mutation Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to effectively characterize and identify deleterious genetic mutations, particularly in genes like BRCA1 and BRCA2, where 80% of variants remain uncharacterized, and 30-40% are classified as Variant of Uncertain Significance due to lack of pathogenicity evidence, overwhelming existing annotation systems.
Innovation Solution
A method involving converting Ramachandran plots of wild-type, benign, and pathogenic proteins into density maps, dividing them into regions, calculating average densities and standard deviations, and comparing unknown proteins to determine deleterious mutations based on density deviations, using molecular dynamics simulation to enhance identification accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current annotation systems are used to characterize genetic variants, then the system capacity is limited, but the quantity of accumulated variation data has far surpassed the capacity
Solution Approach 1:
The patent replaces manual annotation processes with automated computational methods using molecular dynamics simulations and Ramachandran plot analysis. This substitution enables high-throughput processing of genetic variants, transforming the annotation system from a capacity-limited manual process to an automated system capable of handling massive quantities of variation data efficiently
Solution Approach 2:
The patent introduces new analytical parameters including density map calculations from Ramachandran plots, average density, standard deviation, and density deviation metrics. These parameter changes enable systematic classification of variants as pathogenic, benign, or VUS based on quantitative structural deviations, thereby expanding the annotation system's capacity to characterize large volumes of genetic data
2Loss of information
If more genetic variants are characterized, then the understanding of pathogenicity improves, but the proportion of Variant of Uncertain Significance increases due to lack of evidence
Solution Approach 1:
The patent performs preliminary molecular dynamics simulations and Ramachandran plot analyses to establish baseline structural density patterns for wild-type, benign, and pathogenic variants before classifying new variants. This preliminary characterization creates a reference framework that improves the reliability of subsequent classifications, reducing the proportion of VUS by providing pre-established evidence-based criteria
Solution Approach 2:
The patent implements a feedback mechanism where density deviation metrics from Ramachandran plot analyses are continuously refined by comparing classified variants (pathogenic, benign, VUS) against each other. This feedback loop improves classification accuracy by using accumulated evidence from characterized variants to enhance the reliability of future classifications, thereby reducing the proportion of uncertain cases
3Productivity
If manual analysis methods are used for variant characterization, then the analysis depth is sufficient, but the throughput is low and cannot handle massive data
Solution Approach 1:
The patent segments the variant analysis process into distinct computational stages: molecular dynamics simulation, Ramachandran plot generation, density map calculation, statistical analysis, and classification. This segmentation enables automated high-throughput processing while maintaining precision through systematic application of analytical methods at each stage, resolving the contradiction between throughput and accuracy
Data Source
AI summary
A method for identifying deleterious genetic mutations, which method relates to the technical field of biomolecules. The method comprises: respectively converting, into density maps, obtained Ramachandran plots of wild-type proteins, benign protein variants, pathogenic protein variants, and proteins to be identified; dividing each density map into a plurality of regions, and by using the density maps of the benign protein variants, the pathogenic protein variants and the wild-type proteins as a reference, calculating an average density and a standard deviation of each region; if the deviation between the density of the proteins to be identified in each region and the average density of the region exceeds the standard deviation, marking the region as a density deviation region of the proteins to be identified; and on the basis of deviation data of the density deviation region of the proteins to be identified, determining mutations of the proteins to be identified. By means of the method, deleteriousness of unknown mutations can be identified with high throughput, thereby providing an approach for the study of gene mutations associated with cancer and other diseases, and diagnostic methods and therapeutic drugs therefor. The method has broad application prospects.